# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 11-20 of 574 results.
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Jan 31, 2019
Disease(s): Refractory B-Cell Lymphoma
Intervention(s): Anti-CD19 iCAR NK Cells
Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Jan 31, 2019
Disease(s): Refractory B-Cell Lymphoma
Intervention(s): Anti-CD19/CD22 CAR NK Cells
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jan 30, 2019
First Received: Oct 02, 2018
Disease(s): Refractory B-Cell Lymphoma
Intervention(s): Anti-CD22 CAR NK Cells
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Oct 01, 2018
Disease(s): Refractory B-Cell Lymphoma
Intervention(s): Anti-CD19 CAR NK Cells
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
Status: Not yet recruiting
Last Changed: Nov 01, 2019
First Received: Nov 01, 2019
Disease(s): Non-Hodgkin's B-cell Lymphoma
Intervention(s): DZD9008
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Aug 14, 2018
First Received: Apr 11, 2016
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Chidamide, Vinorelbine, Liposomal Doxorubicin or mitoxantrone, Dexamethasone, Thalidomide
Locations: Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
Status: Recruiting
Last Changed: May 14, 2019
First Received: Aug 14, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Tisagenlecleucel, Pembrolizumab
Locations: Emory University School of Medicine SC CTL019, Atlanta, Georgia, United States
University of Chicago Medical Center, Hematology & Oncology, Chicago, Illinois, United States
University of Kansas Hospital and Medical Center U of Kansas Cancer Center, Kansas City, Kansas, United States
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
Novartis Investigative Site, Wien, Austria
... and 3 other locations.
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Status: Recruiting
Last Changed: Oct 16, 2019
First Received: Mar 15, 2019
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Tisagenlecleucel, Ibrutinib
Locations: H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
Status: Recruiting
Last Changed: Aug 22, 2019
First Received: Oct 12, 2018
Disease(s): Refractory Large B-cell Lymphoma
Intervention(s): Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Locations: Stanford Cancer Institute, Palo Alto, California, United States
UCLA Hematology/ Oncology, Santa Monica, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
... and 2 other locations.
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)
Status: Recruiting
Last Changed: Dec 04, 2019
First Received: Jun 28, 2019
Disease(s): Refractory Large B-cell Lymphoma
Intervention(s): Axicabtagene Ciloleucel, Rituximab, Lenalidomide, Fludarabine, Cyclophosphamide
Locations: City of Hope National Medical Center, Duarte, California, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
St. David's South Austin Medical Center, Austin, Texas, United States